Article
PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
Cancer immunology, immunotherapy : CII - 1 Jan 2022
Wang Yanni, Chen Huan, Jiao Xi, Wu Lihong, Yang Ying, Zhang Jiao, Wu Lijia, Liu Chang, Zhuo Na, Li Shuang, Gong Jifang, Li Jian, Zhang Xiaotian, Wang Xicheng, Peng Zhi, Qi Changsong, Wang Zhenghang, Li Jie, Li Yan, Lu Zhihao, Zhang Henghui, Shen Lin
Abstract excerpt
Immunotherapy has emerged as an effective therapeutic strategy for various cancers, including colorectal cancer (CRC), but only a subset of MSI-H patients can benefit from such therapy. Patched1 (PTCH1) is a frequently altered gene in CRCs and its mutations contribute to unregulated Hedgehog (Hh) signaling. In the study, we evaluated the association of PTCH1 mutations with CRC immunity based on our single-center...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.